Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer

A review

Charles Vogel, G. N. Hortobagyi, M. D. Abeloff

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Trials establishing the safety and efficacy of single-agent vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) as first- and second-line chemotherapy for metastatic breast cancer led to testing of the combination of vinorelbine and mitoxantrone. Three phase II clinical trials in Europe and South America, and one phase I trial in the United States have studied the effects of this combination on advanced breast cancer. In the two phase II trials that used vinorelbine and mitoxantrone only, response rates were 56% for patients who received the combination as first-line therapy and 36% for those who were anthracycline resistant. A third phase II trial looked at the effects of a combination of mitoxantrone and vinorelbine plus ifosfamide with means in patients who had failed at least two prior chemotherapy regimens; a 41% response rate was noted. In the phase I trial, the combination of vinorelbine and mitoxantrone with prophylactic granulocyte colony-stimulating factors was explored. Further trials are needed to study the combination of vinorelbine and mitoxantrone.

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalSeminars in Oncology
Volume22
Issue numberSUPPL. 5
StatePublished - Jan 1 1995

Fingerprint

Mitoxantrone
Combination Drug Therapy
Breast Neoplasms
Drug Therapy
Ifosfamide
Phase II Clinical Trials
South America
Anthracyclines
Paris
Granulocyte Colony-Stimulating Factor
vinorelbine
France
Safety
Research

ASJC Scopus subject areas

  • Oncology

Cite this

Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer : A review. / Vogel, Charles; Hortobagyi, G. N.; Abeloff, M. D.

In: Seminars in Oncology, Vol. 22, No. SUPPL. 5, 01.01.1995, p. 61-65.

Research output: Contribution to journalArticle

@article{fc74d2106d4745de9244b888ac556653,
title = "Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: A review",
abstract = "Trials establishing the safety and efficacy of single-agent vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) as first- and second-line chemotherapy for metastatic breast cancer led to testing of the combination of vinorelbine and mitoxantrone. Three phase II clinical trials in Europe and South America, and one phase I trial in the United States have studied the effects of this combination on advanced breast cancer. In the two phase II trials that used vinorelbine and mitoxantrone only, response rates were 56{\%} for patients who received the combination as first-line therapy and 36{\%} for those who were anthracycline resistant. A third phase II trial looked at the effects of a combination of mitoxantrone and vinorelbine plus ifosfamide with means in patients who had failed at least two prior chemotherapy regimens; a 41{\%} response rate was noted. In the phase I trial, the combination of vinorelbine and mitoxantrone with prophylactic granulocyte colony-stimulating factors was explored. Further trials are needed to study the combination of vinorelbine and mitoxantrone.",
author = "Charles Vogel and Hortobagyi, {G. N.} and Abeloff, {M. D.}",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "22",
pages = "61--65",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer

T2 - A review

AU - Vogel, Charles

AU - Hortobagyi, G. N.

AU - Abeloff, M. D.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Trials establishing the safety and efficacy of single-agent vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) as first- and second-line chemotherapy for metastatic breast cancer led to testing of the combination of vinorelbine and mitoxantrone. Three phase II clinical trials in Europe and South America, and one phase I trial in the United States have studied the effects of this combination on advanced breast cancer. In the two phase II trials that used vinorelbine and mitoxantrone only, response rates were 56% for patients who received the combination as first-line therapy and 36% for those who were anthracycline resistant. A third phase II trial looked at the effects of a combination of mitoxantrone and vinorelbine plus ifosfamide with means in patients who had failed at least two prior chemotherapy regimens; a 41% response rate was noted. In the phase I trial, the combination of vinorelbine and mitoxantrone with prophylactic granulocyte colony-stimulating factors was explored. Further trials are needed to study the combination of vinorelbine and mitoxantrone.

AB - Trials establishing the safety and efficacy of single-agent vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) as first- and second-line chemotherapy for metastatic breast cancer led to testing of the combination of vinorelbine and mitoxantrone. Three phase II clinical trials in Europe and South America, and one phase I trial in the United States have studied the effects of this combination on advanced breast cancer. In the two phase II trials that used vinorelbine and mitoxantrone only, response rates were 56% for patients who received the combination as first-line therapy and 36% for those who were anthracycline resistant. A third phase II trial looked at the effects of a combination of mitoxantrone and vinorelbine plus ifosfamide with means in patients who had failed at least two prior chemotherapy regimens; a 41% response rate was noted. In the phase I trial, the combination of vinorelbine and mitoxantrone with prophylactic granulocyte colony-stimulating factors was explored. Further trials are needed to study the combination of vinorelbine and mitoxantrone.

UR - http://www.scopus.com/inward/record.url?scp=0029015482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029015482&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 61

EP - 65

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 5

ER -